头孢他啶-阿维巴坦及对照药物对癌症患者分离出的临床细菌的抗菌活性
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
作者信息
Hachem Ray, Reitzel Ruth, Rolston Kenneth, Chaftari Anne-Marie, Raad Issam
机构信息
Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02106-16. Print 2017 Apr.
Abstract
A total of 521 unique clinical isolates from cancer patients with primarily (>90%) bloodstream infections were tested for susceptibility to ceftazidime-avibactam and comparators using broth microdilution methods. Ceftazidime-avibactam inhibited 97.8% of all ( = 321) at the susceptibility breakpoint of ≤8/4 μg/ml (there were 7 nonsusceptible strains). It was also active against (91.7% isolates susceptible, = 121), including many isolates not susceptible to meropenem, cefepime, ceftazidime, piperacillin-tazobactam, or other comparators.
摘要
使用肉汤微量稀释法，对总共521株主要来自癌症患者（>90%）血流感染的独特临床分离株进行了头孢他啶-阿维巴坦及对照药物的敏感性测试。在≤8/4 μg/ml的敏感折点下，头孢他啶-阿维巴坦抑制了所有321株菌株中的97.8%（有7株不敏感菌株）。它对121株耐碳青霉烯类肠杆菌科细菌（CRE）也有活性（91.7%的分离株敏感），包括许多对美罗培南、头孢吡肟、头孢他啶、哌拉西林-他唑巴坦或其他对照药物不敏感的分离株。
相似文献
1
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.头孢他啶-阿维巴坦及对照药物对癌症患者分离出的临床细菌的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02106-16. Print 2017 Apr.
2
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.头孢他洛滨-他唑巴坦和头孢他啶-阿维巴坦对β-内酰胺类耐药铜绿假单胞菌分离株的活性。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
3
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.2014年美国各医疗中心当代铜绿假单胞菌分离株对头孢他啶-阿维巴坦的体外活性：按普查区域划分
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2537-41. doi: 10.1128/AAC.03056-15. Print 2016 Apr.
4
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of and .2017 年中国抗菌药物监测网（CHINET）对临床分离的 和 的头孢他啶-阿维巴坦和头孢唑南-他唑巴坦活性研究结果。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02431-18. Print 2019 Apr.
5
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.2012年和2013年在美国医疗中心分离出的对多药耐药铜绿假单胞菌的头孢他啶-阿维巴坦活性。
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
6
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.2011年至2015年在美国医疗中心住院治疗肺炎的患者中分离出的革兰氏阴性菌对头孢他啶-阿维巴坦的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02083-16. Print 2017 Apr.
7
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
8
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.2013 年至 2016 年美国医疗中心分离的多药耐药肠杆菌科和铜绿假单胞菌对头孢他啶-阿维巴坦的抗菌活性研究
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01045-17. Print 2017 Nov.
9
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).头孢他啶-阿维巴坦的抗菌活性和谱在测试儿科患者的革兰氏阴性菌时的结果：来自 INFORM 监测计划（美国，2011-2015 年）。
Pediatr Infect Dis J. 2018 Jun;37(6):549-554. doi: 10.1097/INF.0000000000001859.
10
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年（2012年至2015年）期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
引用本文的文献
1
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.革兰氏阴性菌对头孢他啶-阿维巴坦耐药性的全球趋势：系统评价与荟萃分析
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
2
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and .新型β-内酰胺/β-内酰胺酶抑制剂对耐碳青霉烯类肠杆菌科细菌感染的抗菌及诊断管理
Antibiotics (Basel). 2024 Mar 21;13(3):285. doi: 10.3390/antibiotics13030285.
3
Ceftazidime-Avibactam Improves Outcomes in High-Risk Neutropenic Patients with Carbapenemase-Producing Enterobacterales Bacteremia.头孢他啶-阿维巴坦可改善产碳青霉烯酶肠杆菌科细菌血症高危中性粒细胞减少患者的预后。
Microorganisms. 2024 Jan 18;12(1):195. doi: 10.3390/microorganisms12010195.
4
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.耐碳青霉烯类：毒力因子、分子流行病学及治疗选择的最新进展
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
5
Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.氟喹诺酮类杂化分子作为对抗抗菌耐药性的有前景的抗菌剂。
Pharmaceutics. 2022 Aug 22;14(8):1749. doi: 10.3390/pharmaceutics14081749.
6
Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?头孢他啶-阿维巴坦：我们能免受 A 类碳青霉烯酶产生菌感染吗？
Folia Microbiol (Praha). 2021 Dec;66(6):879-896. doi: 10.1007/s12223-021-00918-5. Epub 2021 Sep 9.
7
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).大剂量化疗和自体造血干细胞移植患者感染的预防、诊断和治疗。德国血液学和肿瘤学学会（DGHO）感染病工作组（AGIHO）的建议 2020 年更新。
Ann Hematol. 2021 Feb;100(2):321-336. doi: 10.1007/s00277-020-04297-8. Epub 2020 Oct 20.
8
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.嗜麦芽寡养单胞菌医院获得性肺炎在重症监护病房的结局：一项全国性回顾性研究。
Crit Care. 2019 Nov 21;23(1):371. doi: 10.1186/s13054-019-2649-5.
9
Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.头孢他啶-阿维巴坦的药理学方面和作用谱：系统评价。
Infection. 2018 Apr;46(2):165-181. doi: 10.1007/s15010-017-1096-y. Epub 2017 Nov 7.
10
Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).成人中性粒细胞减少患者不明原因发热（FUO）的诊断与经验性治疗：德国血液学和医学肿瘤学会（DGHO）传染病工作组（AGIHO）指南
Ann Hematol. 2017 Nov;96(11):1775-1792. doi: 10.1007/s00277-017-3098-3. Epub 2017 Aug 30.
本文引用的文献
1
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.头孢他啶/阿维巴坦：一种用于治疗复杂性尿路感染和复杂性腹腔内感染的新型头孢菌素/非β-内酰胺类β-内酰胺酶抑制剂。
Drug Des Devel Ther. 2016 Jul 26;10:2379-86. doi: 10.2147/DDDT.S110946. eCollection 2016.
2
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.头孢他啶/阿维巴坦聚焦：耐多药革兰氏阴性菌感染的新选择。
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
3
The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.血液系统恶性肿瘤患者中多重耐药革兰氏阴性菌感染的威胁日益增加。
Leuk Lymphoma. 2016 Oct;57(10):2245-58. doi: 10.1080/10428194.2016.1193859. Epub 2016 Jun 24.
4
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.在一家主要癌症中心的肠杆菌科血流感染中，发现头孢他啶-阿维巴坦的非敏感性率较高，并鉴定出新型德里金属β-内酰胺酶的产生。
Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.
5
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.2012年至2014年在美国医疗中心对从尿路感染患者中分离出的革兰氏阴性菌进行头孢他啶-阿维巴坦及对照药物抗菌活性研究
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4355-60. doi: 10.1128/AAC.00405-16. Print 2016 Jul.
6
The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013.癌症患者中日益凸显的细菌耐药性问题；MASCC“中性粒细胞减少、感染与骨髓抑制”研究小组在2013年6月27日至29日于柏林举行的MASCC年会上举办的研讨会会议记录
Support Care Cancer. 2016 Jul;24(7):2819-26. doi: 10.1007/s00520-016-3183-5. Epub 2016 Apr 20.
7
Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line-Associated Bloodstream Infections From Oncology Settings, 2009-2012.2009 - 2012年肿瘤病房医疗相关中心静脉导管相关血流感染的病原体及相关耐药性
Clin Infect Dis. 2016 May 15;62(10):1203-9. doi: 10.1093/cid/ciw113. Epub 2016 Mar 1.
8
Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.血液系统癌症患者中与耐碳青霉烯类革兰氏阴性菌感染相关的死亡负担：一项回顾性队列研究。
J Antimicrob Chemother. 2015 Nov;70(11):3146-53. doi: 10.1093/jac/dkv218. Epub 2015 Jul 24.
9
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.头孢他啶/阿维巴坦对重症监护病房（ICU）和非 ICU 患者的革兰氏阴性菌进行了测试，包括呼吸机相关性肺炎患者。
Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14.
10
Antibiotic-resistant gram-negative bacterial infections in patients with cancer.癌症患者的耐抗生素革兰氏阴性菌感染
Clin Infect Dis. 2014 Nov 15;59 Suppl 5(Suppl 5):S335-9. doi: 10.1093/cid/ciu612.
Zotero 插件